Amelyoid-␤ peptide (A␤) is a major causative agent responsible for Alzheimer's disease (AD). A␤ contains a high affinity metal binding site that modulates peptide aggregation and toxicity. Therefore, identifying molecules targeting this site represents a valid therapeutic strategy. To test this hypothesis, a range of L-PtCl2 (L ‫؍‬ 1,10-phenanthroline derivatives) complexes were examined and shown to bind to A␤, inhibit neurotoxicity and rescue A␤-induced synaptotoxicity in mouse hippocampal slices. Coordination of the complexes to A␤ altered the chemical properties of the peptide inhibiting amyloid formation and the generation of reactive oxygen species. In comparison, the classic anticancer drug cisplatin did not affect any of the biochemical and cellular effects of A␤. This implies that the planar aromatic 1,10-phenanthroline ligands L confer some specificity for A␤ onto the platinum complexes. The potent effect of the L-PtCl 2 complexes identifies this class of compounds as therapeutic agents for AD.
A significant body of data indicates the amyloid-␤ peptide (A␤) is a key mediator of the neurodegeneration that occurs in Alzheimer's disease (AD) (1) , although the neurotoxic mechanism(s) and pathway(s) involved remain unresolved (2) . Given its central role in AD, diverse therapeutic strategies that target the generation, disaggregation, and clearance of A␤ are being pursued. Our sequence activity studies have shown that altering the metal binding activity of A␤ inhibits its neurotoxic activity (3, 4) . Methylation of the imidazole side chains of His-6, -13, and -14, which constitute the high affinity metal binding site (5) , changed A␤-metal interactions and A␤:cell binding and rendered the peptide nontoxic (3, 4) . An important conclusion from these studies is that agents, which can target the metal binding site and alkylate the imidazole side chains of A␤ have therapeutic potential.
Platinum anticancer drugs have been used in the clinic for over thirty years, and annual sales exceed one billion U.S. dollars. The structure of the prototypic anti-cancer drug, cisplatin [cisPt(NH 3 ) 2 Cl 2 ] (1) is shown in Fig. 1a . Despite this success, there is scant evidence that Pt-based drugs are viable therapeutics for other diseases. The anticancer Pt compounds have been termed ''DNA alkylators,'' because they bind to the nucleobases of DNA (guanine in particular). These interactions apparently depend on the specific formation of hydrogen bonds between the am(m)ine ligands bound to the Pt and the DNA (6) .
Given the importance of the histidine residues in the A␤ metal binding site (7), we targeted the imidazole side chains as a strategy to inhibit A␤'s neurotoxic activity. Imidazole side chains are excellent ligands for a variety of metal ions, including Pt(II). Our strategy was to design a specific class of ligand that would explicitly target Pt(II) to the histidine residues of A␤. Pt(II) complexes with 1,10-phenanthroline ligands (Fig. 1a) have been well characterized. The ligands themselves have an intrinsic, albeit very weak (approximately millimolar) affinity for A␤ (8) . Because the ligands 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline and 4,7-diphenyl-1,10-phenanthroline interact predominantly with the aromatic residues Phe-4, Tyr-10, and Phe-19 (8) , it was proposed that the ligand-A␤ contacts were mediated through -stacking interactions (8) . The A␤ amino acid sequence (Fig. 1b) shows that the histidine residues (6, 13, and 14) and the aromatic residues are located in the hydrophilic N-terminal domain. The residue most perturbed by the ligand binding, Tyr-10, is located in the middle of the sequence that spans the metal binding site of A␤, whereas Phe-4 and Phe-19 flank the metal binding site. Therefore, we have postulated that Pt(II)-1,10-phenanthroline complexes will also target the Nterminal domain, allowing the Pt to coordinate specifically to this region and so modify the behavior of the A␤ peptide.
We have evaluated three platinum phenanthroline derivatives, Pt(1,10-phenanthroline)Cl 2 (2), Pt(4,7-diphenyl-1,10-phenanth-roline)Cl 2 (3), and Pt(4,7-diphenyl-1,10-phenanthroline disulfonate)Cl 2 (4) (Fig. 1a) ability to inhibit the metal-dependent biochemical and cellular actions of A␤, while using the prototypic anticancer drug cisplatin (1) (Fig. 1a) as a negative control. The work demonstrates that Pt(II)-1,10-phenanthroline complexes coordinate to the histidine residues of A␤ and act as potent inhibitors of A␤-metal chemistry and synaptotoxic activity. These complexes have potential as therapeutic agents for AD.
Results
Selection of Platinum Complexes to Target A␤. Pt compounds (L-PtCl 2 ; L ϭ 1,10-phenanthroline ligand) 2-4 ( Fig. 1a) were selected for testing, because, after loss of chloro ligands, they are predicted to coordinate to the histidine residues of the A␤ peptide and alter its physiochemical and biological properties. Cisplatin (1) lacks the organic scaffold predicted to be necessary to target the Pt(II) metal center to the histidine residues of A␤ and should have little effect on A␤ properties.
Platinum Complexes Bind to A␤. Mass spectrometry. To determine whether the platinum complexes bind to A␤, the L-PtCl 2 2-4 and cisplatin compounds were incubated with A␤1-42 and the product solutions analyzed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectrometry, using 4G8 as the capture antibody. The A␤ peptide alone gave a single peak at 4,515 Ϯ 1 Da, corresponding to its expected mass (4,515 Da) (Fig. 2a) . Incubation of A␤42 overnight with 2 produced a second peak at 4,890 Ϯ 1 Da (Fig. 2a) . The increase in mass of 375-Da units corresponds to the formation of a L-Pt-A␤ adduct in which the two chloro ligands of 2 have been displaced as the compound coordinated to A␤. The mass spectra from the incubation of A␤ with cisplatin, 3 and 4 showed that similar adducts are formed by these compounds (data not shown). NMR spectroscopy. As a ''soft'' metal, Pt has a preference for ligands with ''soft'' donor atoms. Within the A␤ sequence, potential Pt binding sites include the ''soft'' sulfur atom of Met-35 and the imidazole nitrogen atoms of the three histidine side chains that are considered an intermediate between ''hard'' and ''soft'' ligand. In keeping with these preferences, cisplatin has a high affinity for sulfur containing ligands, such as glutathione, but, because of its relatively slow kinetics, it is still able to form complexes with nitrogen-based ligands, such as with the nucleobases of DNA (9) . To confirm that the complexes L-PtCl 2 coordinated the histidine residues of A␤, their interaction with A␤40 was monitored by 1 H NMR. A␤40 was used in these experiments, because its greater solubility and slower aggregation rates over A␤42 allowed NMR experiments to be performed. Spectra recorded before and after the addition of 2 to solutions of A␤40 revealed a strong perturbation of the peaks corresponding to the C4H and C2H of the imidazole side chains of His-6, -13, and -14, consistent with the complex coordinating to these residues (Fig. 2b) . The assignment of these peaks as being due to the imidazole side chains was confirmed by 2D 1 H TOCSY NMR spectra and are consistent with data published in ref. 10 . There was little perturbation of the peak due to C H 3 of Met-35, indicating no significant interaction with this residue. Although the SELDI-TOF MS data indicated that cisplatin was also able to form adducts with A␤; the 1 H NMR spectrum of solutions of 1 with A␤ showed that the nature of these adducts is different from those formed with 2. A reduction in intensity of the peak due C H 3 of Met-35 was observed together with a broadening of the spectrum (Fig. 2b) . These observations are consistent with the formation of A␤ oligomers and multiple other products.
L-PtCl2
Complexes Alter A␤ Secondary Structure: Circular Dichroism Spectroscopy. Aging aqueous solutions of A␤42 in the presence of equimolar Cu 2ϩ results in a conformational change from a predominately random coil conformation to a ␤-sheet conformation ( Fig. 3) (3, 11) . The presence of compounds 2-4 in aging A␤42/Cu 2ϩ solutions induced a change in peptide conformation ( Fig. 3) with a blue shift away from the 215-nm minimum normally associated with classic ␤-sheet structures. Although the spectra of the A␤42/Cu 2ϩ /L-PtCl 2 solutions could not be fitted to any of the classic secondary structure peptide conformations, the observed differences are consistent with different conformations. An alternative explanation for the changes observed is that compounds 2-4 have aromatic ligands and, as such, will absorb in the UV region and when coordinated to the peptide will be in a chiral environment and, therefore, being optically active, give rise to a circular dichroism (CD) signal also in the UV The spectra show that 2 is able to perturb the resonances because of the C4H protons of the imidazole side chains of the three histidine residues, whereas cisplatin does not (see box centered at 7.15 ppm). Conversely, the peak due to the S-CH 3 protons of Met 25 at 2.12 ppm was significantly reduced in intensity after incubation with cisplatin, whereas incubation with 2 does not significantly affect this peak. The peak marked with asterisk was due to acetate impurity present in the peptide samples.
region. Either explanation is consistent with the compounds coordinating to A␤.
Complexes Inhibit A␤ Aggregation. A␤ toxicity is strongly correlated with peptide aggregation. The time-dependent aggregation of A␤ into amyloid fibrillar structures can be followed by using ThT, which gives a characteristic fluorescence signal when bound to amyloid (12) . Compounds 2-4 all inhibited ThT fluorescence in a dose-dependent manner (Fig. 4) , indicating that the formation of amyloidogenic structures was inhibited. This was substantiated by negative staining EM, which showed the generation of amphorous aggregates rather than amyloid fibrils (data not shown). Both ThT and EM showed that cisplatin (1) did not inhibit amyloid formation (data not shown).
L-PtCl2 Complexes Inhibit Copper Redox Chemistry.
We showed that A␤ in the presence of Cu 2ϩ is able to generate H 2 O 2 catalytically (13, 14) . To ascertain whether the Pt complexes could inhibit A␤:Cu 2ϩ -mediated redox chemistry, the complexes were titrated into an A␤:Cu preparation, and H 2 O 2 generation was measured with a fluorimetric assay (13) . The IC 50 values for compounds 1-4 are reported in Table 1 . Although cisplatin had no observable effect, compounds 2-4 inhibited Cu 2ϩ -mediated H 2 O 2 production with an IC 50 in the nanomolar range. This level of inhibition is comparable with that of clioquinol (5-chloro-7-iodo-8-hydroxyquinoline), which inhibits A␤:Cu redox chemistry by directly targeting the Cu rather than the peptide component of the A␤-metal complex (14) .
L-PtCl2
Complexes Inhibit A␤ Neurotoxicity. Having demonstrated that the L-PtCl 2 complexes could bind to the A␤ peptide and change its chemical and structural properties, we assessed their ability to inhibit A␤ toxicity in primary mouse cortical neuronal cell cultures. Treatment of the neurons with 10 M A␤42 for 4 days reduced cell viability to 65% as measured by the MTS assay (Fig. 5) . Coincubation of 10 M A␤42 with 2-4 at either 10 M or 5 M significantly increased cell viability (Fig. 5) . Compound 3 completely restored neuronal viability, whereas cisplatin 1 was inactive at either 5 or 10 M. Compounds 2-4 were not toxic at the concentrations tested (data not shown).
L-PtCl2 Complexes Rescue A␤: Inhibition of Long-Term Potentiation.
Long-term potentiation (LTP) in the rodent hippocampal slice is a measure of synaptic plasticity that focuses on activitydependent persistent increases in synaptic strength and is considered to be the biochemical basis of learning and memory (15, 16) . Synthetic and cell derived A␤ can inhibit LTP in vitro and in vivo and supports the role of A␤ in promoting the learning and memory loss that occurs in AD (17, 18) . The high-frequency stimulation of a mouse hippocampal slice gives an LTP ranging from 148% (Fig. 6b) to 135% (Fig. 6c) . Incubating the hippocampal slice with 2 M A␤42 for 30 min before the stimulus for LTP significantly reduced LTP from 148% to 124% (Fig. 6b) and from 135% to 105% (Fig. 6c) . Compound 3 was chosen as the L-PtCl 2 complex to be tested in the LTP assay as it had the best handling properties with respect to high solubility and low heterogeneity. Conversely, 2 has low solubility, and 4 is heterogeneous because of the multiple positions occupied by the sulfonate groups on the bathophenanthroline ligand. The addition of 4 M compound 3 to the A␤42 solution completely reversed the A␤42-inhibition of LTP (Fig. 6 a and b) . In comparison, 4 M cisplatin did not affect A␤42-dependent inhibition of LTP (Fig. 6c) , supporting the specificity of the effect of 3 being mediated through its organic scaffold. Compound 3 alone did not affect LTP, consistent with specific targeting of the A␤42-dependent inhibition of LTP.
Discussion
The pathological accumulation of A␤ in the brain is a major hallmark of AD. Genetic studies from early onset cases of AD identify alterations in A␤ metabolism as being directly linked to the disease (19) . Although the mechanism of A␤ neurotoxicity is still unknown, it is generally accepted that the A␤ peptide is a valid target for therapeutic development. Because it is unstructured in the native state, the de novo design of effective inhibitors of A␤ is problematic. We have adopted a strategy of using metal compounds that target A␤ specifically by taking advantage of its intrinsic affinity for metal ions. The three histidine residues His-6, -13, and -14 are the A␤ metal binding ligands (5) . Methylation of the imidazole side chains altered Cu binding and inhibited A␤ toxicity (3, 4) . We used Pt(II) complexes to target the A␤-metal binding site. Pt(II) compounds are stable and essentially redox inert when present in biological systems. The slow kinetics associated with substitution reactions at the Pt(II) center means that, once bound to a target, the Pt(II) metal is difficult to displace. The specificity of the interaction between Pt anticancer drugs and DNA has been attributed largely to the ability of the am(m)ine ligands to form hydrogen-bonds to guanine nucleotides of DNA. To promote specific binding to A␤ by L-PtCl2 2-4 complexes, the 1,10-phenanthroline ligand L was designed to target the N-terminal domain of A␤. This was based on the observation that polyaromatic compounds bind to A␤ and inhibit its aggregation (20) . Moreover, the classic amyloid-binding fluorescent dyes Congo red and thioflavin T are also polyaromatic compounds. L-PtCl 2 complexes are highly stable and the likelihood of the chelating ligand, L, dissociating from the metal is remote. We demonstrated that the metal free ligands, L, bind weakly to A␤ via interactions with the aromatic residues Phe-4, Tyr-10 and Phe-19 on A␤ (8) . Importantly for our strategy, these residues span the metal binding residues His-6, -13, and -14.
To establish that the 1,10-phenanthroline ligands were conferring the necessary specificity of action on the Pt complexes, we tested the compound's ability to inhibit key activities of A␤ and compared them with cisplatin, which lacks the polyaromatic ligand (Fig. 1a) . The SELDI-TOF mass spectra and NMR spectra (Fig. 2) indicated that the L-PtCl 2 complexes bound to A␤ as a stable adduct primarily at the histidine residues. In contrast, although cisplatin (1) did form adducts with A␤, it coordinated predominantly at the sulfur atom of Met-35. The ability of the L-PtCl 2 complexes to promote coordination to A␤ via the histidine residues demonstrates that the 1,10-phenanthroline ligands target these residues as predicted.
The coordination of the L-PtCl 2 complexes to A␤ significantly altered the chemical and biophysical properties of the peptide. This is reflected in the altered secondary structure indicated by CD spectra (Fig. 3) , inhibition of amyloid formation (Fig. 4) , and A␤:Cu 2ϩ -mediated redox chemistry (Table 1 ). An interesting observation from these biophysical/chemical studies is that, although the Pt-free 1,10-phenanthroline ligands have a very low millimolar affinity for A␤ (8), the corresponding Pt complexes are potent inhibitors of A␤. This reflects that Pt chemistry is kinetically, rather than thermodynamically, controlled. Therefore, even though the low affinity of L for A␤ should result in short residency times with the intended target, the kinetic inertness of Pt complexes means that, once bound to the target, the L-Pt:A␤ adducts are very stable and will not dissociate. The synergistic effect of coupling the low affinity ligand and kinetically stable Pt is highlighted by the lack of activity by the cisplatin in inhibiting either amyloid formation or A␤:Cu 2ϩ redox chemistry. The inability of cisplatin to inhibit A␤:Cu 2ϩ -mediated redox chemistry is interesting, because cisplatin will coordinate to Met-35, and this residue has been implicated in the redox chemistry of A␤ (21, 22) .
A key test of the L-PtCl 2 complexes potential efficacy is their ability to alter the biological properties of A␤ in a cellular system. We examined the compounds ability to rescue A␤ induced toxicity in primary neuronal cell cultures and A␤ induced inhibition of LTP in hippocampal neuronal slices. All three L-PtCl 2 complexes rescued A␤ induced toxicity in the primary cortical neurons, whereas cisplatin was inactive. The mechanism of A␤ toxicity is still unclear, with proposed mechanisms dependent on a variety of A␤ biophysical and chemical properties, such as peptide aggregation, and the ability of A␤ to coordinate metal ions, such as copper and zinc (2) . Changes in the CD profile and the inhibition of amyloid formation indicated that the L-PtCl 2 complexes altered the structural properties of A␤. Because the L-PtCl 2 complexes coordinate to the histidine residues of A␤, they occupy the zinc and copper binding site on A␤ and so inhibit metal-mediated phenomena, such as ROS generation.
Having established that the L-PtCl 2 complexes inhibit A␤ neurotoxicity, we investigated whether an example of this class of compound could rescue A␤-induced inhibition of LTP. Compound 3 was chosen as the L-PtCl 2 complex to be tested in this assay, because it had the best handling properties with respect to high solubility and low heterogeneity. Conversely, 2 has low solubility, and 4 is heterogeneous because of the multiple positions occupied by the sulfonate groups on the bathophenanthroline ligand. Electrophysiological recordings of LTP in the hippocampal slice measure the level of synaptic strengthening after high-frequency stimulation of a population of synaptically connected neurons. Because changes in synaptic strength are thought to underlie the learning and memory processes, the LTP assay and A␤ inhibition of LTP is an established method for investigating A␤ synaptotoxicity (17, 18) and assessing putative AD-therapeutic compounds. Compound 3 completely reversed the A␤ induced inhibition of LTP, whereas, in the absence of A␤, it did not significantly alter the levels of LTP (Fig. 6) . Importantly, cisplatin did not affect either LTP or rescue A␤-inhibition of LTP, thus supporting the specificity of 3. These cellular results demonstrate the potency, specificity, and efficacy of this compound in reducing the neurotoxic and synaptotoxic activities of A␤.
The data presented here indicate that the 1,10-phenanthroline complexes of Pt(II) coordinate to the histidine imidazole side chains of A␤ and alter the biochemical and biophysical properties of the peptide. Importantly, these alterations to the physical properties of A␤ potently inhibit the peptides neurotoxic and synaptotoxic actions. The inactivity of cisplatin indicates that the aromatic 1,10-phenanthroline scaffold coordinated to Pt(II) conferred the necessary specific targeting of the Pt to the histidine residues of A␤. The results achieved with the L-PtCl 2 complexes support the future development of this class of compound as therapeutic agents for AD to ensure they efficiently cross the blood-brain barrier. The potent effects of these Pt complexes define the histidine residues of A␤ as a viable therapeutic target to inhibit the neurotoxic and synaptotoxic actions of A␤.
Materials and Methods
Pt complexes 1 and 2 were purchased from Aldrich; 3 and 4 were prepared as described in ref. 23 . Peptides were obtained from AusPep and from the W. M. Keck Laboratory (Yale University, New Haven, CT). 2 H2O was obtained from Cambridge Isotope Laboratories. Stock solutions of 2, 3, and 4 were prepared by dissolving known amounts of the compounds in DMSO to give a final concentration of 4 mM. A␤ Peptide Preparation. Dry A␤1-42 or A␤1-40 peptide was weighed and dissolved in hexafluro-2-isopropanol (HFIP) and incubated at 25°C for 1 h to remove any preformed aggregates. It was then aliquotted into known amounts and dried by using a speed-vac. The dry peptide was stored at Ϫ80°C. Aliquots were dissolved in 20 mM NaOH and diluted 1:10 with PBS (pH 7.4) and sonicated in a water bath containing ice for 15 min. The solution was then centrifuged in a bench-top centrifuge at 16,000 ϫ g for 20 min, and the supernatant was stored on ice until used. Initial peptide concentrations were determined by spectrophotometry at 214 nm, using an extinction coefficient of 75,887 liters⅐mol Ϫ1 ⅐cm Ϫ1 . NMR Spectroscopy. Samples for NMR were run in aqueous PBS with 10% 2 H2O added. Samples containing A␤40 were run at 0.3 mM. The compounds were incubated with A␤ at 30°C for 2 h. NMR spectra were recorded on Bruker DRX-600 and AMX-500 spectrometers as described in ref. 5 .
SELDI-TOF Mass Spectrometry. A␤ Pt drug adducts were analyzed by using PS10 ProteinChip arrays (Ciphergen Biosystems). Two microliters of antibody (4G8) in PBS (0.25 mg/ml) was added to the spots of the PS10 chip, which was incubated in the humidified chamber at 4°C overnight. The antibody was removed, and blocking buffer (0.5 M ethanolamine in PBS) was added (5 l). The array was incubated for 30 min. The blocking buffer was removed, and each spot was washed with 5 l of 0.5% Triton X-100/PBS (wash buffer) for 5 min. The solvent was removed, and the spots were washed with 5 l of PBS for 5 min. A 60-l sample was added to each spot, and the array was incubated at room temperature for 3 h. The samples were removed, and each spot was washed twice with 60 l of wash-buffer for 5 min. Each spot was washed with 60 l of PBS twice for 5 min and then washed with 60 l of 1 mM Hepes twice for 1 min. The array was air-dried. One microliter of sinapinic acid (SPA) [50% saturated in 50% (vol/vol) acetonitrile and 0.5% in TFA] was applied to each spot twice. The array was air-dried between each application. All incubations and washes were performed on a shaking table. Chips were analyzed in a PBSIIC protein chip reader; SELDI-TOF MS and peaks were analyzed by using Ciphergen ProteinChip software, Version 3.1.
CD Spectroscopy. A␤ peptide was prepared as described above and incubated at 37°C. The final peptide concentration was determined to be 26 M, and it was incubated in the presence of equimolar Cu 2ϩ alone or equimolar Cu 2ϩ plus 26 M 2, 3, or 4.
Synchrotron radiation circular dichroism spectra were collected on station 12.1 at the Synchrotron Radiation Source, Daresbury Laboratory (Warrington, U.K.). Data were collected at 37°C in a 0.02-cm fused silica cell with a peptide concentration of 26 M. Data were collected between 195 and 260 nm in 0.5-nm increments with 1-s accumulation at each wavelength. Background readings of buffer in the absence of peptide were subtracted. Spectra were smoothed by using a Fourier transform. Inhibition of H2O2 Generated by A␤:Cu. H2O2 production by A␤ peptides was measured by using a fluorimetric assay described in ref. 13 . Dichlorofluorescein diacetate (DCF) (Molecular Probes) was dissolved (5 mM) in 100% dimethyl sulfoxide (argon purged for 2 h at 20°C), deacetylated with 0.25 M NaOH for 30 min, and neutralized (pH 7.4) to a final concentration of 1 mM. Horseradish peroxidase (HRP) stock solution was prepared to 1 M in PBS (pH 7.4). The reactions were carried out in PBS (pH 7.4) under ambient conditions in a 96-well plate (250 l per well) containing freshly prepared synthetic peptide (up to 1 M), Cu-Gly (up to 2 M), reducing agents (up to 10 M), deacetylated DCF (100 M), and HRP (0.1 M) incubated at 37°C. EDTA (10 M) was included to prevent reactions with contaminating concentrations (Ϸ0.2 M) of free Cu 2ϩ . The concentrations of A␤ used varied to bring readout values into a convenient target range. A␤ was used at 200 nM. Studies were completed on the day of reagent preparation. Reactions were conducted in the dark to avoid photodynamic effects. The signal specific for H2O2 was the decrease in fluorescence of parallel samples coincubated with catalase (4,000 units/ml; 10 M). Fluorescent readings were recorded by a Packard Fluorocount plate reader (485-nm excitation, 530-nm emission) against a standard curve of reagent-grade H2O2 in PBS (pH 7.4). A␤ Neurotoxicity. Primary neuronal cultures and Cell viability assay were prepared and carried out as described in ref. 24 . Data are shown as mean Ϯ SE. Statistical comparisons between groups were done with Student's t test.
Long-Term Potentiation. 14 to 40-day-old C57Bl6 mice were decapitated under anesthesia by halothane inhalation in accordance with University of Melbourne animal ethics guidelines. Brains were rapidly removed and chilled in ice-cold artificial cerebral spinal fluid (ACSF). ACSF contained 124 mM NaCl, 2.5 mM KCl, 2 mM MgSO4, 2 mM CaCl 2 , 10 mM D-glucose, 1.25 mM NaH 2 PO 4 , and 26 mM NaHCO3 and was gassed with 95% O2 and 5% CO2 (pH 7.35) (HCl⅐NaHCO3). A␤1-42 (3) and cisplatin were dissolved in DMSO and preincubated on the slices for 30 min in ACSF vehicle with DMSO levels controlled at 0.3%. All experiments were interleaved and conducted at room temperature. Field potential recordings were made in 350-m transverse sections of the hippocampus by stimulating and recording in the stratum radiatum of the CA1 region. Recordings were made with an NPI microelectrode amplifier in bridge-mode, connected to a 20ϫ preamplifier with a 10-kHz low-pass eightpole Bessel filtration (Krohn-Hite; model 3381 filter/amplifier). Signals were digitized with a Digidata 1322A A/D converter (Axon Instruments) and stored in pClamp software, Versions 8.2 or 9.0 (Axon Instruments). Baseline stimulation intensity was calibrated at the beginning of each experiment to produce responses of 20 -30% of the maximum slope of the field excitatory post synaptic potential (fEPSP). Tetanic stimulation was a 1-s 100-Hz pulse delivered at the test intensity in substitution for the test stimulus. Data were analyzed offline, using pClamp 8.2, Microsoft Excel, and GraphPad Prism 3.03 programs. The slope of each fEPSP was determined by linear regression of the data points between the peak of the presynaptic fiber volley and the peak of the fEPSP. Normalized fEPSP slopes were expressed as the percentage of the average slope of the baseline between 30 to 20 min before tetanus. Long-term potentiation was quantified by averaging the normalized data 55-60 min after tetanus for each slice. Results were presented as the means Ϯ SE, and statistical significance was determined by using an unpaired t test at the 95% confidence interval.
Experimental Treatment Protocol for Brain Slices. Slices were transferred to a 24-well plate and preincubated in gassed ACSF at room temperature with or without experimental compounds for 30 min immediately before electrophysiological recording. A␤42 was dissolved in HFIP, dried, resuspended in DMSO, and stored in small aliquots at Ϫ20°C. A␤42 aliquots were rapidly thawed and used immediately. Compound 3 and cisplatin were dissolved in DMSO immediately before use. Final DMSO concentrations were controlled at 0.3% in all preincubations.
